Corbus Pharmaceuticals Holdings, Inc. (CRBP) investor relations documents from the company's IR site: 1 presentation, 28 press releases; latest deck 2026-06-18. Read in-app with summaries. First-party data.
Corporate Presentation: Corbus Pharmaceuticals' June 2026 presentation highlights CRB-701, a Nectin-4 ADC showing 42.9% cORR in 2L+ OPSCC patients at the 3.6 mg/kg dose.
CRBP overview · CRBP earnings · CRBP financials · CRBP KPIs · CRBP ownership · CRBP peers · CRBP filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.